Detail

Study ID: COG ARST1431

Title:

A Randomized Phase 3 Study of Vincristine, Dactinomycin,Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI)Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC#683864, IND#122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Location:
Fargo Region
Principal Investigator:
Samuel Anim, MD
Disease:
RST (Soft Tissue Sarcoma), Sarcoma, Soft Tissue
Stage:
Phase III
Status:
Active - Open to Accrual